Publications

​

Genomic and epigenomic studies on neuroendocrine tumors

Tirosh A, Killian JK, Petersen D, Zhu YJ, Walker RL, Blau JE, Nilubol N, Patel D, Agarwal SK, Weinstein LS, Meltzer P, Kebebew E. Distinct DNA Methylation Signatures in Neuroendocrine Tumors Specific for Primary Site and Inherited Predisposition. JCEM 2020 (10.1210/clinem/dgaa477)

 

Tirosh A, Killian JK, Zhu YJ, Petersen D, Walling J, Meltzer P, Kebebew E. Oncogene panel sequencing analysis identifies candidate actionable genes in advanced well-differentiated gastroenteropancreatic neuroendocrine tumors. Endocr Pract 2019 (10.4158/EP-2018-0603)

 

Tirosh A, Mukherjee S, Lack J, Gara SK, Wang S, Quezado MM, Keutgen XM, …, Nilubol N, Tyagi MV, Kebebew E. Distinct genome-wide methylation patterns in sporadic and hereditary nonfunctioning pancreatic neuroendocrine tumors. Cancer 2019 (10.1002/cncr.31930)

 

Tirosh A, Sadowski SM, Linehan WM, Libutti SK, Patel D, Nilubol N, Kebebew E. Association of VHL Genotype With Pancreatic Neuroendocrine Tumor Phenotype in Patients With von Hippel-Lindau Disease. JAMA Oncol 2018 (10.1001/jamaoncol.2017.3428)

 

Tirosh A, El Lakis M, Green P, Linehan WM, Kebebew E. In silico VHL Gene Mutation Analysis and Prognosis of Pancreatic Neuroendocrine Tumors in von Hippel-Lindau Disease. JCEM 2018 (10.1210/jc.2017-02434)

 

Clinical research – hereditary neuroendocrine tumors

​

Halperin R, Arnon L, Nasirov S, Friedensohn L, Gershinsky G, Telerman A, Friedman F, Bernstein-Molho R, Tirosh A. Germline CDKN1B variant type and site are associated with phenotype in MEN 4. Endocrine Related Cancer, Dec 2022, 30(1):e220174 (doi: 10.1530/ERC-22-0174)

​

Peltz-Sinvani N, Percik R, Uri I, Kfir SK, Tirosh A, Tirosh A. Low risk for all-cause mortality among patients with lung neuroendocrine tumors co-diagnosed with pituitary adenomas. Endocrine 2021 (10.1007/s12020-021-02740-y)

 

Kfir SK, Halperin R, Percik R, Uri I, Halpern N, Shlomai G, Laish I, Tirosh A, Tirosh A. Distinct Prognostic Factors in Sporadic and Multiple Endocrine Neoplasia Type 1-Related Pancreatic Neuroendocrine Tumors. Horm Metab Res 2021 (10.1055/a-1464-1276)

 

Studies focusing on VHL

​

Halperin R, Arnon L, Eden-Friedman Y, Tirosh. Unique Characteristics of Patients with von Hippel-Lindau Disease Defined by Various Diagnostic Criteria. Cancrers, 2023 Mar; 15(6):1657 (doi: 10.3390/cancers15061657)

​

Shell J, Tirosh A, Millo C, Sadowski SM, Assadipour Y, Green P, Patel D, Nilubol N, Kebebew E. The utility of (68)Gallium-DOTATATE PET/CT in the detection of von Hippel-Lindau disease associated tumors. Eur J Radiol 2019 (10.1016/j.ejrad.2018.11.023)

​

Tirosh A, Journy N, Folio LR, Lee C, Leite C, Yao J, Kovacs W, Linehan WM, Malayeri A, Kebebew E, Berrington de González A. Cumulative Radiation Exposures from CT Screening and Surveillance Strategies for von Hippel-Lindau-associated Solid Pancreatic Tumors. Radiology 2019 (10.1148/radiol.2018180687)

​

Arnon L, Halperin R, Tirosh A. Impact of Pancreatic Neuroendocrine Tumor on Mortality in Patients With von Hippel-Lindau Disease. Endocr Pract 2021 (10.1016/j.eprac.2021.03.005)

 

Clinical research – sporadic neuroendocrine tumors

​

Halperin, R., Aharon-Hananel, G., Badarna, M., Greidinger, D., Uri, I., Percik, R., Tirosh, A. Plasma hemoglobin and red blood cell mass levels as dynamic prognostic markers for progression and survival in pancreatic neuroendocrine tumors, Hormone and Metabolic Research,2021Dec; 53(12):810-817 (10.1055/a-1672-4653)

​

Tirosh A, Papadakis GZ, Millo C, …, Keutgen XM, Patel D, Nilubol N, Kebebew E. Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients With Neuroendocrine Tumors. Gastroenterology 2018 (10.1053/j.gastro.2017.11.008)

 

Badarna M, Percik R, Aharon-Hananel G, Uri I, Tirosh A. Anatomic site as prognostic marker of pancreatic neuroendocrine tumors: a cohort study. Eur J Endocrinol 2019 (10.1530/EJE-19-0332)

 

Tirosh A, Papadakis GZ, Millo C, Patel D, Nilubol N, Kebebew E. Association between neuroendocrine tumors biomarkers and primary tumor site and disease type based on total (68)Ga-DOTATATE-Avid tumor volume measurements. Eur J Endocrinol 2017 (1530/EJE-16-1079)

 

Tirosh A, Nilubol N, Patel D, Kebebew E.  Prognostic Utility of 24-Hour Urinary 5-HIAA Doubling Time in Patients With Neuroendocrine Tumors. Endocr Pract 2018 (10.4158/EP-2018-0022)

 

Nockel P, Tirosh A, El Lakis M, et al. Incidence and management of postoperative hyperglycemia in patients undergoing insulinoma resection. Endocrine 2018 (10.1007/s12020-018-1633-1)

 

Tirosh A, Stemmer SM, Solomonov E, Elnekave E, Saeger W, Ravkin Y, Nir K, Talmor Y, Shimon I. Pasireotide for malignant insulinoma. Hormones 2016 (10.14310/horm.2002.1639)

​

Collaborations

Tirosh Amir, Tuncman G, Calay ES, Rathaus M, Ron I, Tirosh Amit, Yalcin A, Lee YG, Livne R, Ron S, Minsky N, Arruda AP, Hotamisligil GS. Intercellular Transmission of Hepatic ER Stress in Obesity Disrupts Systemic Metabolism. Cell Metab 2021 (10.1016/j.cmet.2020.11.009)

 

Trivellin G, Tirosh A, Hernández-Ramírez LC, Gupta T, Tsai-Morris CH, Faucz FR, Burgess HA, Feldman B, Stratakis CA. The X-linked acrogigantism-associated gene gpr101 is a regulator of early embryonic development and growth in zebrafish. Mol Cell Endocrinol 2021 (10.1016/j.mce.2020.111091)

Neumann HPH, Tsoy U, Bancos I, Amodru V, Walz MK, Tirosh A, …, Bausch B, Young WF Jr, Eng C; International Bilateral-Pheochromocytoma-Registry Group. Comparison of Pheochromocytoma-Specific Morbidity and Mortality Among Adults With Bilateral Pheochromocytomas Undergoing Total Adrenalectomy vs Cortical-Sparing Adrenalectomy. JAMA Netw Open 2019 (10.1001/jamanetworkopen.2019.8898)

 

Makri A, Bonella MB, Keil MF, Hernandez-Ramirez L, Paluch G, Tirosh A, Saldarriaga C, Chittiboina P, Marx SJ, Stratakis CA, Lodish M. Children with MEN1 gene mutations may present first (and at a young age) with Cushing disease. Clin Endocrinol (Oxf) 2018 (10.1111/cen.13796).

 

Reviews

 

Halperin R, Tirosh A. Non-Interventional Management of Advanced Pancreatic Neuroendocrine Neoplasms in Patients with von Hippel-Lindau Disease. Cancers, 2023 Mar; 15(6):1739 (doi: 10.3390/cancers15061739)

​

Tirosh A, Kebebew E. Genetic and epigenetic alterations in pancreatic neuroendocrine tumors. J Gastrointest Oncol 2020 (10.21037/jgo.2020.03.11)

 

Tirosh A, Kebebew E. The utility of (68)Ga-DOTATATE positron-emission tomography/computed tomography in the diagnosis, management, follow-up and prognosis of neuroendocrine tumors. Future Oncol 2018 (10.2217/fon-2017-0393)

 

Tirosh A, Valdés N, Stratakis CA. Genetics of micronodular adrenal hyperplasia and Carney complex. Presse Med 2018 (10.1016/j.lpm.2018.07.005).

 

Completed projects

Tirosh A, Jin DX, De Marco L, Laitman Y, Friedman E. Activating genomic alterations in the Gs alpha gene (GNAS) in 274 694 tumors. Genes Chromosomes Cancer 2020 (10.1002/gcc.22854)

 

Tirosh A, Hamimi A, Faucz F, Aharon-Hananel G, Zavras PD, Bonella B, Auerbach A, Gillis D, Lyssikatos C, Belyavskaya E, Stratakis CA, Gharib AM. Liver findings in patients with Carney complex, germline PRKAR1A pathogenic variants, and link to cardiac myxomas. Endocr Relat Cancer 2020 (10.1530/ERC-19-0517).

 

Assaf D, Gutman Y, Neuman Y, Segal G, … , Tirosh A. Utilization of machine-learning models to accurately predict the risk for critical COVID-19. Intern Emerg Med 2020 (10.1007/s11739-020-02475-0)

 

Laitman Y, Tzur S, Attai R, Tirosh A, Friedman E. Germline variant in REXO2 is a novel candidate gene in familial pheochromocytoma Genet Res (Camb) 2020 (10.1017/S0016672320000038)

 

Tirosh A, RaviPrakash H, Papadakis GZ, Tatsi C, Belyavskaya E, Charalampos L, Lodish MB, Bagci U, Stratakis CA. Computerized Analysis of Brain MRI Parameter Dynamics in Young Patients With Cushing Syndrome - A Case-Control Study. JCEM 2020 (10.1210/clinem/dgz303)

 

Aharon-Hananel G, Percik R, Badarna M, Uri I, Tirosh A. Lower all-cause mortality rates in patients harboring pituitary carcinoma following the introduction of temozolomide. Endocrine 2019 (10.1007/s12020-019-01996-9)

​

Lectures

 

During the VHL alliance 2022 meeting, both Prof Tirosh and Dr Halperin presented the team's research results via oral presentations. Dr Halperin discussed how using different diagnostic criteria may erroneously lead to false diagnosis of VHL, in a talk titled: “Unique characteristics of von Hippel-Lindau disease-associated pancreatic neuroendocrine tumors by various diagnostic criteria”, while Prof Tirosh described our insight on the impact of VHL-related pancreatic neuroendocrine tumors, on the immune response against the tumor cells.